The Marked Chart Wire · Business
BioMarin
BioMarin forecasts 2026 revenue of $3.8B to $3.9B
BioMarin projects full-year 2026 revenue between $3.8 billion and $3.9 billion. The company also noted $70 million in order deferrals.
The stocks in this story
Prices from Before the open · based on Mon close · Opens 9:30 AM ET. Each tile opens the stock's chart and news.
New to this? Read: Reading a stock chart
More Business news
Merck
Merck sells US contract manufacturing unit to Lonza
Merck has agreed to exit its US contract development and manufacturing organization business by selling the division to Lonza.
Philips
Philips Q3 profit falls on legal costs, EBITDA rises
Koninklijke Philips reported a sharp drop in third-quarter profit due to a Respironics settlement provision, while adjusted EBITDA increased on higher sales. The company maintained its full-year 2026 outlook.
Palantir
Palantir third-quarter revenue rises 96 percent to $2.3 billion
Palantir posted $2.3 billion in sales for the third quarter, marking a 96 percent jump from the prior-year period.
Vertex
Vertex sets 2026 revenue guidance at $13.15 billion to $13.25 billion
Vertex Pharmaceuticals projects 2026 revenue between $13.15 billion and $13.25 billion. The guidance includes $40 million to $50 million from Crinetics.
HotGrab Earnings
GRAB Holdings raises guidance after revenue growth
Grab Holdings reported that third-quarter revenue increased by 27 percent. The company also raised its financial guidance, causing the stock to move in after-hours trading.
HotGrab
GRAB reports mixed third quarter results and raises outlook
Grab released its third quarter earnings, describing the performance as mixed. The company also increased its full year 2026 financial outlook.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.